We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Oxytocin to Decrease Blood Loss During Cesarean Section

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00891150
Recruitment Status : Completed
First Posted : May 1, 2009
Last Update Posted : March 6, 2013
Sponsor:
Information provided by (Responsible Party):
Dr. Labib Ghulmiyeh, American University of Beirut Medical Center

Brief Summary:
The goal of this study is to determine the best dose of a drug called oxytocin, that is usually used to stop bleeding during a delivery, when used during a cesarean delivery. It will be administered during cesarean section in order to decrease the amount blood loss. The investigators are proposing to have 3 groups of subjects each given a different safe dose of oxytocin and then to assess the effectiveness of each regimens on the amount blood lost during cesarean sections.This will let use know which is the best lowest dose needed.

Condition or disease Intervention/treatment
Complications; Cesarean Section Drug: Oxytocin

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Official Title: Intravenous Oxytocin Use to Decrease Blood Loss During Cesarean Section. What is the Optimal Dose: A Randomized Blinded Trial
Study Start Date : July 2012
Primary Completion Date : February 2013
Study Completion Date : February 2013

Resource links provided by the National Library of Medicine

Drug Information available for: Oxytocin
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: oxytocin
group 1 will receive oxytocin solutions with 20U/500ml during cesarean section
Drug: Oxytocin

Pre-mixed, oxytocin solutions with either 20U/500ml, 30U/500ml or 40U/500ml of Lactated Ringer's solution will be available in the pharmacy department. The bags will be identical in appearance. Each bag will be labeled with a study identification number, from which the pharmacy could determine the administered dose. Subjects as well as the medical providers will be blinded to the assignment of the solution used.

Immediately after delivery of the infant, the study solution will be infused over 30 minutes using a continuous infusion pump (666 mU/min versus 999 mU/min versus 1332mU/min).

Other Name: Pitocin
Active Comparator: oxytocin2
group 2 will receive oxytocin solutions with 30U/500ml during cesarean section
Drug: Oxytocin

Pre-mixed, oxytocin solutions with either 20U/500ml, 30U/500ml or 40U/500ml of Lactated Ringer's solution will be available in the pharmacy department. The bags will be identical in appearance. Each bag will be labeled with a study identification number, from which the pharmacy could determine the administered dose. Subjects as well as the medical providers will be blinded to the assignment of the solution used.

Immediately after delivery of the infant, the study solution will be infused over 30 minutes using a continuous infusion pump (666 mU/min versus 999 mU/min versus 1332mU/min).

Other Name: Pitocin
Active Comparator: oxytocin3
group 3 will receive oxytocin solutions with 40U/500ml during cesarean section
Drug: Oxytocin

Pre-mixed, oxytocin solutions with either 20U/500ml, 30U/500ml or 40U/500ml of Lactated Ringer's solution will be available in the pharmacy department. The bags will be identical in appearance. Each bag will be labeled with a study identification number, from which the pharmacy could determine the administered dose. Subjects as well as the medical providers will be blinded to the assignment of the solution used.

Immediately after delivery of the infant, the study solution will be infused over 30 minutes using a continuous infusion pump (666 mU/min versus 999 mU/min versus 1332mU/min).

Other Name: Pitocin



Primary Outcome Measures :
  1. The change in hemoglobin as a measure of blood loss. The change in hemoglobin is defined as the difference between the predelivery hemoglobin value and the postpartum value [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. The need for blood transfusion and the use of additional uterotonic agents, pad weight, pad count, estimated blood loss. [ Time Frame: 1 year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   15 Years to 45 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Study subjects will be women delivering via an elective cesarean section at term
  • All study subjects will have singleton gestation with no obstetric or medical complication.

Exclusion Criteria:

  • Laboring women
  • Multifetal gestation
  • Prolonged oxytocin use (>12 hours)
  • Hypertensive disorders
  • Chorioamnionitis
  • Suspected macrosomia
  • Polyhydramnios
  • History of postpartum Hemorrhage
  • Clotting disorder
  • Intake of magnesium sulfate
  • Uterine fibroids
  • Placenta previa
  • Placental abruption
  • Anticoagulation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00891150


Locations
Lebanon
American University of Beirut Medical Center
Beirut, Lebanon
Sponsors and Collaborators
American University of Beirut Medical Center
Investigators
Principal Investigator: Labib M Ghulmiyyah, MD American University of Beirut Medical Center

Responsible Party: Dr. Labib Ghulmiyeh, Assistant Professor, American University of Beirut Medical Center
ClinicalTrials.gov Identifier: NCT00891150     History of Changes
Other Study ID Numbers: OGY.LB.01
First Posted: May 1, 2009    Key Record Dates
Last Update Posted: March 6, 2013
Last Verified: March 2013

Additional relevant MeSH terms:
Oxytocin
Oxytocics
Reproductive Control Agents
Physiological Effects of Drugs